A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
A phase 3 trial of Lutetium[177Lu] Oxodotreotide Injection in neuroendocrine tumours, run by Sinotau Pharmaceutical Group, active and no longer recruiting.
Overview
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs is a phase 3 interventional study registered as NCT05459844 by Sinotau Pharmaceutical Group, with 196 participants enrolled, started 2022-08-31 and due to reach its primary completion in 2024-06-26. Interventions recorded: Lutetium[177Lu] Oxodotreotide Injection and Octreotide LAR.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Shares Sinotau Pharmaceutical, Neuroendocrine tumours and the tag pipeline.
- TrialStudy of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Shares Neuroendocrine tumours and the tag pipeline.
- TrialDose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Shares Neuroendocrine tumours and the tag pipeline.
- TrialDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With NEN
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Shares Neuroendocrine tumours and the tag pipeline.